Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehdi Touat

Showing results (41-50 of 93) with videos related to

Pageof 10
Sort By:
Neurology|May 6, 2018
<i>FGFR1</i> actionable mutations, molecular specificities, and outcome of adult midline gliomasAlberto Picca, Giulia Berzero, Franck Bielle, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2024
REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomasAlberto Picca, Mehdi Touat, Lisa Belin, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
A Predictive Clinical-Radiomics Nomogram for Survival Prediction of Glioblastoma Using MRISamy Ammari, Raoul Sallé de Chou, Corinne Balleyguier, et al.
Neuropathology and Applied Neurobiology|September 30, 2025
A Specific Methylation Class Identifies BAP1-Deficient Meningiomas, Including Meningeal Tumours With Poorly Differentiated Nonrhabdoid HistologyPhilippe Drabent, Mehdi Touat, Patrick R Benusiglio, et al.
Journal of Neurosurgery|February 28, 2025
Safety and therapeutic impact of stereotactic biopsy in very elderly patients with brain tumorsLouise Deboeuf, Maximilien Riche, Henri Malaizé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2026
18F-DOPA-PET and advanced MRI improve treatment response assessment in IDH1/2-mutant gliomas treated with IDH inhibitorsDiego Prost, Lucia Nichelli, Laura Rozenblum, et al.
The Oncologist|July 27, 2019
Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen-Activated Protein Kinase Pathway AlterationsWilliam Boisseau, Philipp Euskirchen, Karima Mokhtari, et al.
Journal of Neurosurgery|September 10, 2021
Severity, timeline, and management of complications after stereotactic brain biopsyMaximilien Riche, Pauline Marijon, Aymeric Amelot, et al.
Neuropathology and Applied Neurobiology|July 28, 2023
A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutantSuzanne Tran, Alice Thomas, Ilyes Aliouat, et al.
Neuropathology and Applied Neurobiology|September 23, 2023
Hippocampal and neocortical BRAF mutant non-expansive lesions in focal epilepsiesJulie Lerond, Bertrand Mathon, Mélina Scopin, et al.
Pageof 10

Showing results (41-50 of 93) with videos related to

Sort By:
Pageof 10
Neurology|May 6, 2018
<i>FGFR1</i> actionable mutations, molecular specificities, and outcome of adult midline gliomasAlberto Picca, Giulia Berzero, Franck Bielle, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2024
REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomasAlberto Picca, Mehdi Touat, Lisa Belin, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
A Predictive Clinical-Radiomics Nomogram for Survival Prediction of Glioblastoma Using MRISamy Ammari, Raoul Sallé de Chou, Corinne Balleyguier, et al.
Neuropathology and Applied Neurobiology|September 30, 2025
A Specific Methylation Class Identifies BAP1-Deficient Meningiomas, Including Meningeal Tumours With Poorly Differentiated Nonrhabdoid HistologyPhilippe Drabent, Mehdi Touat, Patrick R Benusiglio, et al.
Journal of Neurosurgery|February 28, 2025
Safety and therapeutic impact of stereotactic biopsy in very elderly patients with brain tumorsLouise Deboeuf, Maximilien Riche, Henri Malaizé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2026
18F-DOPA-PET and advanced MRI improve treatment response assessment in IDH1/2-mutant gliomas treated with IDH inhibitorsDiego Prost, Lucia Nichelli, Laura Rozenblum, et al.
The Oncologist|July 27, 2019
Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen-Activated Protein Kinase Pathway AlterationsWilliam Boisseau, Philipp Euskirchen, Karima Mokhtari, et al.
Journal of Neurosurgery|September 10, 2021
Severity, timeline, and management of complications after stereotactic brain biopsyMaximilien Riche, Pauline Marijon, Aymeric Amelot, et al.
Neuropathology and Applied Neurobiology|July 28, 2023
A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutantSuzanne Tran, Alice Thomas, Ilyes Aliouat, et al.
Neuropathology and Applied Neurobiology|September 23, 2023
Hippocampal and neocortical BRAF mutant non-expansive lesions in focal epilepsiesJulie Lerond, Bertrand Mathon, Mélina Scopin, et al.
Pageof 10